Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Costs and Expenses:
General and administrative	$ 5,029	$ 4,580
Research and development	5,131	11,083
Total Operating Costs and Expenses	10,160	15,663
Loss from Operations	(10,160)	(15,663)
Other Income :
Interest income	44	283
Total Other Income	44	283
Net Loss	(10,116)	(15,380)
Net Loss Attributable to Non-controlling Interest	(73)	(77)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(10,043)	(15,303)
Preferred Stock Dividends, Income Statement Impact	(254)	(248)
Effect of Warrant exercise price adjustment	(880)	0
Net Loss Attributable to Common Stockholders	$ (12,557)	$ (16,076)
Net Loss Per Share - Basic and Dilutive	$ (0.66)	$ (0.98)
Weighted average number of shares outstanding during the period - Basic and Dilutive	19,011,362	16,438,201
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (254)	$ (248)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (1,380)	$ (525)